Results in more detail indicate that 528 women (including 10 twin pregnancies) had 538 known outcomes as follows: 459 live births (85.3%), 47 miscarriages (8.7%), 27 elective abortions (5.0%), and 5 stillbirths (0.9%). There were 8 major congenital malformations (1.7%) among the 459 infants. First trimester exposure occurred for 367/452 (81.2%) pregnancies resulting in 459 live births. Exposure during all 3 trimesters occurred for 201/452 (44.5%) pregnancies. The authors state that this analysis represents the largest cohort of pregnant women exposed to an anti‐TNF for management of chronic inflammatory diseases.